Literature DB >> 24735967

Premalignant PTEN-deficient thymocytes activate microRNAs miR-146a and miR-146b as a cellular defense against malignant transformation.

Megan L Burger1, Ling Xue1, Yuefang Sun1, Chulho Kang1, Astar Winoto1.   

Abstract

Cancer develops by a multistep process during which cells acquire characteristics that allow them to evade apoptosis and proliferate unchecked. Sequential acquisition of genetic alterations drives this process but also causes cellular stress, frequently prompting cells to enter a premalignant period during which they mount a defense against transformation. T cell-specific deletion of the tumor suppressor PTEN in mice induces premalignancy in the thymus and development of CD4(+) T-cell lymphomas in the periphery. Here we sought to identify factors mediating the cellular defense against transformation during the premalignant period. We identified several microRNAs upregulated specifically in premalignant thymocytes, including miR-146a, miR-146b, and the miR-183/96/182 cluster. CD4-driven T cell-specific transgenic overexpression of mir-146a and mir-146b significantly delayed PTEN-deficient lymphomagenesis and delayed c-myc oncogene induction, a key driver of transformation in PTEN-deficient T-cell malignancies. We found that miR-146a and miR-146b targeting of Traf6 attenuates TCR signaling in the thymus and inhibits downstream NF-κB-dependent induction of c-myc. Additionally, c-myc repression in mature CD4 T cells by miR-146b impaired TCR-mediated proliferation. Hence, we have identified 2 miRNAs that are upregulated as part of the cellular response against transformation that, when overrepresented, can effectively inhibit progression to malignancy in the context of PTEN deficiency.
© 2014 by The American Society of Hematology.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24735967      PMCID: PMC4073325          DOI: 10.1182/blood-2013-11-539411

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  48 in total

1.  T cell-specific loss of Pten leads to defects in central and peripheral tolerance.

Authors:  A Suzuki; M T Yamaguchi; T Ohteki; T Sasaki; T Kaisho; Y Kimura; R Yoshida; A Wakeham; T Higuchi; M Fukumoto; T Tsubata; P S Ohashi; S Koyasu; J M Penninger; T Nakano; T W Mak
Journal:  Immunity       Date:  2001-05       Impact factor: 31.745

2.  Modulation of microRNA expression in human T-cell development: targeting of NOTCH3 by miR-150.

Authors:  Margherita Ghisi; Alberto Corradin; Katia Basso; Chiara Frasson; Valentina Serafin; Subhamoy Mukherjee; Lara Mussolin; Katia Ruggero; Laura Bonanno; Alessandro Guffanti; Gianluca De Bellis; Gino Gerosa; Giovanni Stellin; Donna M D'Agostino; Giuseppe Basso; Vincenzo Bronte; Stefano Indraccolo; Alberto Amadori; Paola Zanovello
Journal:  Blood       Date:  2011-05-06       Impact factor: 22.113

3.  Mature T cells depend on signaling through the IKK complex.

Authors:  Marc Schmidt-Supprian; Gilles Courtois; Jane Tian; Anthony J Coyle; Alain Israël; Klaus Rajewsky; Manolis Pasparakis
Journal:  Immunity       Date:  2003-09       Impact factor: 31.745

4.  Distinct roles for PTEN in prevention of T cell lymphoma and autoimmunity in mice.

Authors:  Xiaohe Liu; Jodi L Karnell; Bu Yin; Ruan Zhang; Jidong Zhang; Peiying Li; Yongwon Choi; Jonathan S Maltzman; Warren S Pear; Craig H Bassing; Laurence A Turka
Journal:  J Clin Invest       Date:  2010-07       Impact factor: 14.808

5.  An emerging player in the adaptive immune response: microRNA-146a is a modulator of IL-2 expression and activation-induced cell death in T lymphocytes.

Authors:  Graziella Curtale; Franca Citarella; Claudia Carissimi; Marina Goldoni; Nicoletta Carucci; Valerio Fulci; Debora Franceschini; Francesca Meloni; Vincenzo Barnaba; Giuseppe Macino
Journal:  Blood       Date:  2009-11-12       Impact factor: 22.113

6.  Identification of miR-145 and miR-146a as mediators of the 5q- syndrome phenotype.

Authors:  Daniel T Starczynowski; Florian Kuchenbauer; Bob Argiropoulos; Sandy Sung; Ryan Morin; Andrew Muranyi; Martin Hirst; Donna Hogge; Marco Marra; Richard A Wells; Rena Buckstein; Wan Lam; R Keith Humphries; Aly Karsan
Journal:  Nat Med       Date:  2009-11-08       Impact factor: 53.440

7.  T-cell lymphomas in T-cell-specific Pten-deficient mice originate in the thymus.

Authors:  T J Hagenbeek; H Spits
Journal:  Leukemia       Date:  2007-11-29       Impact factor: 11.528

8.  MicroRNA signatures associated with cytogenetics and prognosis in acute myeloid leukemia.

Authors:  Ramiro Garzon; Stefano Volinia; Chang-Gong Liu; Cecilia Fernandez-Cymering; Tiziana Palumbo; Flavia Pichiorri; Muller Fabbri; Kevin Coombes; Hansjuerg Alder; Tatsuya Nakamura; Neal Flomenberg; Guido Marcucci; George A Calin; Steven M Kornblau; Hagop Kantarjian; Clara D Bloomfield; Michael Andreeff; Carlo M Croce
Journal:  Blood       Date:  2008-01-10       Impact factor: 22.113

9.  Normal development is an integral part of tumorigenesis in T cell-specific PTEN-deficient mice.

Authors:  Ling Xue; Hector Nolla; Akira Suzuki; Tak W Mak; Astar Winoto
Journal:  Proc Natl Acad Sci U S A       Date:  2008-02-04       Impact factor: 11.205

10.  Function of miR-146a in controlling Treg cell-mediated regulation of Th1 responses.

Authors:  Li-Fan Lu; Mark P Boldin; Ashutosh Chaudhry; Ling-Li Lin; Konstantin D Taganov; Toshikatsu Hanada; Akihiko Yoshimura; David Baltimore; Alexander Y Rudensky
Journal:  Cell       Date:  2010-09-17       Impact factor: 41.582

View more
  12 in total

1.  Ablation of miR-146b in mice causes hematopoietic malignancy.

Authors:  Takahiro Mitsumura; Yoshiaki Ito; Tomoki Chiba; Takahide Matsushima; Ryota Kurimoto; Yoko Tanaka; Tomomi Kato; Keisuke Uchida; Takashi Ito; Kouhei Yamamoto; Yoshinobu Eishi; Masanobu Kitagawa; Yasunari Miyazaki; Naohiko Inase; Hiroshi Asahara
Journal:  Blood Adv       Date:  2018-12-11

2.  miR-146b antagomir-treated human Tregs acquire increased GVHD inhibitory potency.

Authors:  Yunjie Lu; Keli L Hippen; Amanda L Lemire; Jian Gu; Weizhi Wang; Xuhao Ni; Parvathi Ranganathan; Bruce L Levine; James L Riley; Carl H June; Laurence A Turka; David H Munn; Ramiro Garzon; Ling Lu; Bruce R Blazar
Journal:  Blood       Date:  2016-08-02       Impact factor: 22.113

3.  MicroRNA-146b promotes PI3K/AKT pathway hyperactivation and thyroid cancer progression by targeting PTEN.

Authors:  Julia Ramírez-Moya; León Wert-Lamas; Pilar Santisteban
Journal:  Oncogene       Date:  2018-01-22       Impact factor: 9.867

Review 4.  Non-coding RNAs: the new central dogma of cancer biology.

Authors:  Phei Er Saw; Xiaoding Xu; Jianing Chen; Er-Wei Song
Journal:  Sci China Life Sci       Date:  2020-09-11       Impact factor: 6.038

5.  MiR-146b negatively regulates migration and delays progression of T-cell acute lymphoblastic leukemia.

Authors:  Nádia C Correia; Rita Fragoso; Tânia Carvalho; Francisco J Enguita; João T Barata
Journal:  Sci Rep       Date:  2016-08-23       Impact factor: 4.379

6.  A 3-miRNA signature predicts prognosis of pediatric and adolescent cytogenetically normal acute myeloid leukemia.

Authors:  Ruiqi Zhu; Weiwei Zhao; Fengjuan Fan; Liang Tang; Jingdi Liu; Ting Luo; Jun Deng; Yu Hu
Journal:  Oncotarget       Date:  2017-06-13

7.  miR-146a promotes growth of osteosarcoma cells by targeting ZNRF3/GSK-3β/β-catenin signaling pathway.

Authors:  Chun Zhou; Chang-Qing Jiang; Zhen Zong; Jia-Chen Lin; Li-Feng Lao
Journal:  Oncotarget       Date:  2017-07-19

8.  Long noncoding RNA MALAT1 inhibits the apoptosis and autophagy of hepatocellular carcinoma cell by targeting the microRNA-146a/PI3K/Akt/mTOR axis.

Authors:  Ningfu Peng; Jingrong He; Jindu Li; Hao Huang; Weiqiao Huang; Yingyang Liao; Shaoliang Zhu
Journal:  Cancer Cell Int       Date:  2020-05-13       Impact factor: 5.722

9.  MicroRNA Mechanisms of Action: What have We Learned from Mice?

Authors:  Hyun Yong Jin; Changchun Xiao
Journal:  Front Genet       Date:  2015-11-16       Impact factor: 4.599

Review 10.  Genetic Alterations of TRAF Proteins in Human Cancers.

Authors:  Sining Zhu; Juan Jin; Samantha Gokhale; Angeli M Lu; Haiyan Shan; Jianjun Feng; Ping Xie
Journal:  Front Immunol       Date:  2018-09-20       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.